Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. Class A

VERA

0.00

Evercore ISI Group analyst Gavin Clark-Gartner maintains Vera Therapeutics (NASDAQ: VERA) with a Outperform and lowers the price target from $95 to $91.